Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study

Hypertensive Disease Clinical Trial

Official title:

Implications of Maternal 45,X Mosaicism As A Secondary Genomic Finding Following Cell-free DNA Sequencing During Pregnancy: A Deep Phenotype Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05548881
• Other study ID #: 10000137
• Secondary ID: 000137-CH
• Status: Not yet recruiting
• Start date: June 26, 2024
• Est. completion date: December 31, 2042

Study information

• Verified date: June 17, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Harveen Kaur
• Phone: (301) 451-1777
• Email: harveen.kaur[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

Mosaicism is a condition in which cells within the same person have a different genetic makeup. Sometimes, a type of mosaicism called 45,X may not be discovered in a woman until she undergoes routine tests during pregnancy. Little is known about how 45,X mosaicism may affect a person s long-term health.

Objective:

This natural history study will look for health risks in people with 45,X mosaicism.

Eligibility:

People aged 18 to 99 years who during pregnancy were found to have 45,X mosaicism. Healthy volunteers are also needed.

Design:

Participants will stay in the clinic for 2 days. They will have many tests:

A physical exam, including measurements of the body.

A gynecological exam, including genital measurements. Photos may be taken, with consent.

Blood tests, with blood drawn over an 8-week period. An oral glucose test for diabetes may also be done.

Tests of heart function. Participants will have small stickers attached to wires place on their chest, arms, and legs.

Hearing tests.

Ultrasound exams, which use echoing sound waves to create images of organs such as the heart and kidneys.

Imaging scans including x-rays, MRI, and DXA. The DXA uses x-rays to measure bone density and body fat. Other types of scans will capture images of the liver.

Participants will complete 4 surveys with questions about their sexual function, anxiety, depression, and health.

Participants may remain in the study for 20 years. For 5 years, they will have a yearly follow-up by phone or email. They may have follow-up visits at the clinic every 5 years.

Description:

Study Description:

This is a deep phenotype study of women who are determined to have 45,X mosaicism as a secondary genomic finding following cfDNA sequencing during pregnancy.

Objectives:

• To define and describe a comprehensive phenotype of women with confirmed 45,X mosaicism initially found by cfDNA including cardiovascular, skeletal, metabolic, reproductive, audiometric, immunologic, and psychological functions.

• To compare the comprehensive phenotype of women with confirmed 45,X mosaicism with a control population (a. age and BMI-matched female controls without 45, X mosaicism at the initial visit and b. NHANES age-and BMI-matched female data for the applicable year.)

• To explore changes in phenotype for both 45,X mosaicism and control groups with somatic loss of X chromosome over time.

Endpoints:

Primary Endpoint: (i) Hypertension (as defined in 2017 by the American College of Cardiology/American Heart Association (ACC/AHA)

Secondary Endpoints:

• Cardiovascular:

• Cardiac/coronary atherosclerosis

• Cardiac function, valve assessment, aortic anatomy, endothelial function

• Skeletal:

• Height

• Areal bone mineral density (aBMD) as per DXA

• Bone turnover markers

• Bone microarchitecture using trabecular bone score as per DXA

• Occult fractures using vertebral fracture assessment as per DXA

• Skeletal morphology for assessment of scoliosis

• Metabolic:

• Body fat distribution as per DXA

• Anthropometrics; Body weight; Waist to hip ratio

• Diabetes Mellitus

• Thyroid disorders

• Dyslipidemia

• Assessment of liver for fatty disease and fibrosis as per abdominal MRE/MRS

• Gynecologic and urologic:

• Markers of gonadal function and ovarian reserve

• Primary ovarian insufficiency, Infertility, Early menopause as per participant history

• Sexual function (as assessed by scores of the Female Sexual Function Index (FSFI) and the PROMIS(Registered Trademark) Sexual Function and Satisfaction Measures Version 2.0)

• Ovarian and uterine imaging as per pelvic ultrasound.

• Renal imaging as per renal ultrasound

• Obstetric:

--Complications and outcomes of pregnancy as per participant history

• Audiometric:

--Assessment of hearing loss

• Immunologic

• Immune biomarkers

• Celiac disease

• Psychological:

• PROMIS(Registered Trademark) Item Bank v1.0 - Emotional Distress - Anxiety - Short Form 8a

• PROMIS(Registered Trademark) Item Bank v.1.0 - Emotional Distress - Depression - Short Form 8b

• PROMIS(Registered Trademark) Scale v.1.2 - Global Health

Exploratory endpoints: Changes in phenotype (as outlined above) for both 45,X mosaicism and control groups with somatic loss of X chromosome over time.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 240
• Est. completion date: December 31, 2042
• Est. primary completion date: December 31, 2042
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 99 Years

Eligibility

• INCLUSION CRITERIA:

Individuals of all races/ethnicities are eligible to participate.

• Individuals assigned female sex at birth ages >=18 to <= 99 years old who have not undergone medical and/or surgical transgender treatment

• Suspected maternal 45,X mosaicism as a secondary genomic finding following cfDNA sequencing during pregnancy

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Ability of subject to understand and the willingness to sign a written informed consent document.

• Ability to read and comprehend written and verbal English as the documents required for the study have not been translated for non-English speaking speakers.

Inclusion criteria for control subjects:

• Individuals assigned female sex at birth ages >=18 to <= 99 years old who have not undergone medical and/or surgical transgender treatment

• Good general health. In general, subjects should take no medications. The use of over the counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication prior to study entry may be still eligible.

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Ability of subject to understand and the willingness to sign a written informed consent document.

• Ability to read and comprehend written and verbal English as the documents required for the study have not been translated for non-English speaking speakers.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria at screening or baseline will be excluded from participation in this study:

• Male and transfemale individuals

• Individuals with significant medical comorbidities (e.g. NYHA Class III or IV heart failure, or CKD Stage 3b or worse (eGFR < 60 mL/min/1.73 m2), or American Society of Anesthesiologists Physical Status Class 3 or above) or other serious disorders at the discretion of the investigators.

• Individuals who have current substance abuse or a DSM 5 Axis I psychiatric disorder or DSM Axis II Mental Retardation diagnosis that in the opinion of the investigators would impede competence, compliance, or participation in the study

Exclusion criteria for control subjects:

• Male and transfemale individuals

• Individuals with significant medical comorbidities (e.g. NYHA Class III or IV heart failure, or CKD Stage 3b or worse (eGFR < 60 mL/min/1.73 m2), or American Society of Anesthesiologists Physical Status Class 3 or above) or other serious disorders at the discretion of the investigators.

• For females of reproductive potential: use of oral contraceptive pills, contraceptive patch, contraceptive vaginal ring within the past 3 months; use of depo medroxyprogesterone within the past 6 months; use of the etonorgestrel contraceptive implant within the past 1 month.

• Individuals who are pregnant, planning to become pregnant, currently nursing an infant, or have irregular menses, defined as cycles less than 21 days or greater than 45 days in premenopausal women.

• Previous history of the following: malignancy, chemotherapy, radiation therapy, primary ovarian insufficiency, galactosemia.

• Individuals who have current substance abuse or a DSM 5 Axis I psychiatric disorder or DSM Axis II Mental Retardation diagnosis that in the opinion of the investigators would impede competence, compliance, or participation in the study.

• Current use of tobacco or nicotine (eg. Nicotine patch, e-cigarette) products.

• Individuals who have had prior ear surgery other than myringotomy, individuals with cochlear implants, individuals who require use of hearing aids.

Related Conditions & MeSH terms

• Hypertension
• Hypertensive Disease

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hypertension	Evaluation of hypertension as defined in 2017 by the American College of Cardiology/American Heart Association (ACC/AHA): Normal blood pressure - Systolic <120 mmHg and diastolic <80 mmHg	5 Years

External Links

•   NIH Clinical Center Detailed Web Page